Crescent Biopharma (CBIO) Competitors $11.72 -0.31 (-2.58%) As of 10/3/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CBIO vs. GERN, MYGN, VSTM, RIGL, LXRX, EBS, XOMA, VNDA, CDXS, and IRWDShould you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Lexicon Pharmaceuticals (LXRX), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry. Crescent Biopharma vs. Its Competitors Geron Myriad Genetics Verastem Rigel Pharmaceuticals Lexicon Pharmaceuticals Emergent Biosolutions XOMA Royalty Vanda Pharmaceuticals Codexis Ironwood Pharmaceuticals Crescent Biopharma (NASDAQ:CBIO) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Is CBIO or GERN more profitable? Crescent Biopharma has a net margin of 0.00% compared to Geron's net margin of -53.52%. Geron's return on equity of -31.37% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Crescent BiopharmaN/A -106.06% -86.60% Geron -53.52%-31.37%-16.01% Do analysts recommend CBIO or GERN? Crescent Biopharma presently has a consensus price target of $25.60, indicating a potential upside of 118.43%. Geron has a consensus price target of $3.79, indicating a potential upside of 180.42%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Crescent Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Geron 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 Which has more risk & volatility, CBIO or GERN? Crescent Biopharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Does the media refer more to CBIO or GERN? In the previous week, Crescent Biopharma had 2 more articles in the media than Geron. MarketBeat recorded 3 mentions for Crescent Biopharma and 1 mentions for Geron. Crescent Biopharma's average media sentiment score of 0.87 beat Geron's score of 0.59 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in CBIO or GERN? 75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.0% of Crescent Biopharma shares are owned by company insiders. Comparatively, 7.4% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, CBIO or GERN? Crescent Biopharma has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrescent Biopharma$10K22,912.60-$37.88M-$34.93-0.34Geron$76.99M11.19-$174.57M-$0.13-10.38 SummaryCrescent Biopharma beats Geron on 11 of the 17 factors compared between the two stocks. Get Crescent Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.13M$2.63B$6.14B$10.58BDividend YieldN/A56.38%5.67%4.69%P/E Ratio-0.3424.2285.3826.71Price / Sales22,912.60726.66605.26131.81Price / CashN/A172.1237.9061.31Price / Book1.425.3412.556.55Net Income-$37.88M$32.92M$3.31B$277.50M7 Day Performance-5.71%3.90%4.28%2.42%1 Month Performance-17.70%8.79%6.90%8.63%1 Year PerformanceN/A-3.79%70.54%31.60% Crescent Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOCrescent Biopharma4.425 of 5 stars$11.72-2.6%$25.60+118.4%N/A$229.13M$10K-0.3450News CoveragePositive NewsShort Interest ↑GERNGeron2.9355 of 5 stars$1.37+4.6%$3.79+176.3%-68.8%$874.08M$164.45M-10.5470MYGNMyriad Genetics3.6839 of 5 stars$7.23-0.1%$12.45+72.3%-69.6%$672.72M$832.90M-1.692,700VSTMVerastem2.4828 of 5 stars$8.83+2.2%$13.29+50.5%+203.1%$543.44M$2.14M-2.6950RIGLRigel Pharmaceuticals3.6546 of 5 stars$28.33-1.5%$38.20+34.8%+77.9%$508.24M$179.28M5.24160LXRXLexicon Pharmaceuticals2.8476 of 5 stars$1.35-2.9%$3.23+138.9%-16.6%$490.59M$58.43M-4.09140Analyst UpgradeEBSEmergent Biosolutions4.3985 of 5 stars$8.81-1.5%$13.50+53.2%-2.4%$470.02M$812.50M3.602,420Positive NewsXOMAXOMA Royalty4.1917 of 5 stars$38.54+3.6%$69.50+80.3%+43.7%$465.87M$12.77M-24.8610News CoverageVNDAVanda Pharmaceuticals4.2848 of 5 stars$4.99+1.6%$16.50+230.7%+17.3%$294.85M$203.47M-4.42290CDXSCodexis3.2982 of 5 stars$2.44-0.8%$11.00+350.8%-19.6%$220.26M$59.35M-2.94250Positive NewsIRWDIronwood Pharmaceuticals4.4176 of 5 stars$1.31-7.7%$4.94+277.1%-64.0%$212.78M$351.41M-26.19220Positive News Related Companies and Tools Related Companies Geron Competitors Myriad Genetics Competitors Verastem Competitors Rigel Pharmaceuticals Competitors Lexicon Pharmaceuticals Competitors Emergent Biosolutions Competitors XOMA Royalty Competitors Vanda Pharmaceuticals Competitors Codexis Competitors Ironwood Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CBIO Stock Alerts